1、China Life Sciences&Health Care TeamMarch 2025China LSHC Industry Survey China LSHC Industry Survey 2025 State of Industry in China2China Life Science&Health Care Industry Survey 2025 State of Industry in China 2025.For information,contact Deloitte China.Content Framework Results Questions&Deep-dive

2、China LSHC Business Outlook&ConsiderationsNew regulatory and technology impactNew shifts in business investment strategy Concluding insights Appendix3China Life Science&Health Care Industry Survey 2025 State of Industry in China 2025.For information,contact Deloitte China.Note:SOE State-owned Enterp

3、rise;POE Private-owned Enterprise;JV Joint Venture;WOFE Wolly Foreign-owned Enterprises:HC HealthcareSurvey period:January 2025(closed February 7,2025)Engaged 125 China-based Life Science&Health Care(LSHC)industry operators and investorsFramework56%11%25%8%WOFEJVPOESOE23%42%34%Chairman/CEOC-suite le

4、velOther management team74%4%18%4%BiopharmaMedTechDistributorsHC services46%23%15%16%Over 5 billion1-5 billion100 million-1billionLess than 100millionCompany type distributionIndustry sector distributionSeniority level distributionChina revenue(RMB)size distribution4China Life Science&Health Care In

5、dustry Survey 2025 State of Industry in China 2025.For information,contact Deloitte China.China LSHC outlook&considerations5China Life Science&Health Care Industry Survey 2025 State of Industry in China 2025.For information,contact Deloitte China.Note:Large cos company with 2024 revenue exceed RMB 1

6、 billion;SOE State-owned Enterprise;POE Private-owned Enterprise;WOFE Wolly Foreign-owned EnterprisesWhile Chinas business performance in 2024 exceeded that of 2023,it remained below expectations.Local players continued to face heightened commercialization pressures throughout the year China LSHC in